Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$0.35
-7.7%
$0.38
$0.30
$3.33
$8.17M-1.37169,736 shs415,503 shs
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$4.97
+4.2%
$13.27
$4.30
$658.60
$2.01M5.7774,634 shs111,298 shs
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$1.08
-2.7%
$1.09
$0.72
$8.09
$8.57M0.35357,674 shs449,693 shs
Biomerica, Inc. stock logo
BMRA
Biomerica
$3.18
-6.2%
$3.73
$1.93
$10.16
$8.10M0.37277,396 shs42,908 shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-7.74%-11.68%-15.68%-44.98%-85.97%
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
+4.19%+1.02%-50.35%-91.03%-99.98%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-2.70%0.00%-14.29%-31.65%-85.60%
Biomerica, Inc. stock logo
BMRA
Biomerica
-6.19%0.00%-11.91%-41.85%-32.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
2.5 of 5 stars
3.53.00.00.03.31.70.0
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
3.1727 of 5 stars
3.55.00.00.04.10.00.6
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
4.4095 of 5 stars
3.55.00.04.72.60.80.6
Biomerica, Inc. stock logo
BMRA
Biomerica
0.9687 of 5 stars
0.05.00.00.02.70.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
3.00
Buy$8.002,198.85% Upside
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
3.00
Buy$219,040.004,407,143.46% Upside
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
3.00
Buy$30.002,677.78% Upside
Biomerica, Inc. stock logo
BMRA
Biomerica
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest APVO, ACXP, BMRA, and BCLI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$8.00
3/19/2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/A$0.34 per shareN/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
$3.11M0.65N/AN/A$3.26 per share1.52
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/A($1.20) per shareN/A
Biomerica, Inc. stock logo
BMRA
Biomerica
$5.68M1.43N/AN/A$0.39 per share8.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$14.58M-$0.70N/AN/AN/AN/A-392.36%-223.78%8/8/2025 (Estimated)
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$24.13MN/A0.00N/AN/AN/A-488.93%-152.51%8/14/2025 (Estimated)
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$17.19M-$3.36N/AN/AN/AN/AN/A-528.56%8/13/2025 (Estimated)
Biomerica, Inc. stock logo
BMRA
Biomerica
-$5.98M-$2.32N/AN/A-100.52%-90.19%-64.54%N/A

Latest APVO, ACXP, BMRA, and BCLI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
-$84.20-$87.80-$3.60-$4.39N/AN/A
5/15/2025Q1 2025
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$0.38-$0.45-$0.07-$0.45N/AN/A
5/12/2025Q1 2025
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.14-$0.11+$0.03-$0.11N/AN/A
4/14/2025Q3 2025
Biomerica, Inc. stock logo
BMRA
Biomerica
N/A-$0.48N/A-$0.06N/A$1.12 million
3/17/2025Q4 2024
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.18-$0.16+$0.02-$0.16N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/AN/A
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/AN/A
Biomerica, Inc. stock logo
BMRA
Biomerica
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/A
1.80
1.80
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
N/A
1.72
1.72
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/A
0.05
0.05
Biomerica, Inc. stock logo
BMRA
Biomerica
N/A
3.17
2.22

Institutional Ownership

CompanyInstitutional Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
11.53%
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
8.06%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
14.33%
Biomerica, Inc. stock logo
BMRA
Biomerica
22.28%

Insider Ownership

CompanyInsider Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
29.60%
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
0.01%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
11.15%
Biomerica, Inc. stock logo
BMRA
Biomerica
15.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
323.48 million11.99 millionOptionable
Aptevo Therapeutics Inc. stock logo
APVO
Aptevo Therapeutics
50405,0001.46 millionNot Optionable
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
407.94 million5.32 millionOptionable
Biomerica, Inc. stock logo
BMRA
Biomerica
602.55 million15.59 millionOptionable

Recent News About These Companies

Biomerica, Inc.: Biomerica Announces Reverse Stock Split
Biomerica Inc trading halted, news pending
Biomerica reports Q3 EPS ($1.20) vs ($1.90) last year
Biomerica Announces Reverse Stock Split
Biomerica Reports Third Quarter Fiscal 2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acurx Pharmaceuticals stock logo

Acurx Pharmaceuticals NASDAQ:ACXP

$0.35 -0.03 (-7.74%)
Closing price 06/3/2025 04:00 PM Eastern
Extended Trading
$0.36 +0.01 (+2.01%)
As of 06/3/2025 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Aptevo Therapeutics stock logo

Aptevo Therapeutics NASDAQ:APVO

$4.97 +0.20 (+4.19%)
Closing price 06/3/2025 04:00 PM Eastern
Extended Trading
$5.10 +0.13 (+2.52%)
As of 06/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Brainstorm Cell Therapeutics stock logo

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.08 -0.03 (-2.70%)
Closing price 06/3/2025 04:00 PM Eastern
Extended Trading
$1.08 -0.01 (-0.46%)
As of 06/3/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Biomerica stock logo

Biomerica NASDAQ:BMRA

$3.18 -0.21 (-6.19%)
Closing price 06/3/2025 03:52 PM Eastern
Extended Trading
$3.35 +0.17 (+5.31%)
As of 06/3/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.